Obermatt
See Similar Stocks →

Novozymes

CPH:NSIS B · DK0060336014
ChemicalsX-Large

360

45
EV / EBIT10
Price / Owner Earnings36
Owner Earnings Yield49
Dividend Yield39
Price/Sales5
EV / Gross Profit22
Price/Book22
Return on Capital25
Cash Return on Capital47
Return on Equity29
EBIT Margin89
Gross Profitability21
Cash Conversion78
Accruals7
Owner Earnings Margin94
Sales growth76
Profit Growth83
Long-Term EPS Growth33
Owner Earnings Growth42
Reinvestment82
Price momentum21
Debt load78
Refinancing16
Debt Payback61
Liquidity93
Analyst ratings67
Opinion Changes64
Price Target Upside74
Market mood92
Value Creation10/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Novozymes clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryDenmark
IndustryChemicals
SizeX-Large
TypePublic Company
ExchangeCPSE
Employees5,769
Websitenovozymes.com
ISINDK0060336014
Last UpdateApr 2, 2026
Indices
OMX C20 (Denmark)Renewable Energy Users
Themes
NutraceuticalClean EnergyCleanTechAnimal FeedBiofuelAgriTechBio-based and Renewable MaterialsBiomass EnergyFarmingBiotechnologyEnergyInnovation Management

Description

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics. The company focuses on sustainable solutions that enhance the efficiency of various processes across multiple industries, including agriculture, food and beverages,…

Analysis

Hope premium

Novozymes A/S is priced well ahead of what the underlying numbers justify, a pattern we describe as a hope premium.

On valuation, the picture is expensive. The owner-earnings multiple stands at 32.2×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 13% a year, against analyst forecasts of 7%. The gap between price and consensus is worth watching: demanding expectations.

Growth is moderate; the safety picture is sturdy. The company scores 10/20 on our value-creation score: creating some value.

Flags to be aware of: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
80
2023202420252026

All-time high

80

Jun 2026

All-time low

23

Feb 2026

Average rank

55

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
5
3
5
7
Price/Earnings
5
7
5
1
Price/Book
22
16
1
1
Dividend Yield
39
30
52
34
Value (overall)
8
4
10
3

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Novozymes with its peers
DSM-Firmenich
AEX:DSFIR
23
CountrySwitzerland
IndustryChemicals
SizeX-Large
Full Stock Analysis →
BRAIN Biotech
GER:BNN
40
CountryGermany
IndustryChemicals
SizeSmall
Full Stock Analysis →
Symrise
GER:SY1
27
CountryGermany
IndustryChemicals
SizeLarge
Full Stock Analysis →
Fermentalg
PAR:ALGAE
39
CountryFrance
IndustryChemicals
SizeX-Small
Full Stock Analysis →
Tessenderlo
BRU:TESB
64
CountryBelgium
IndustryChemicals
SizeLarge
Full Stock Analysis →
Bioceres Crop
NSQ:BIOX
15
CountryUK
IndustryChemicals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →